Baxter, Hikma Pharmaceuticals sales and marketing update

Hikma will acquire Baxter's U.S. generic injectables business for about $112 million in cash. The business, which had 2009 revenues of $169.7 million, includes products sold primarily in the U.S. to treat chronic pain and infection. As part of the deal, about 750 Baxter employees will transfer over to Hikma, which will also acquire a Baxter manufacturing facility, warehouse and distribution center. ...